VivoSeq
Hematology

Von Willebrand Disease

28

Pipeline Programs↗

10

Active Trials↗

10

Companies Involved↗

Von Willebrand disease is an emerging landscape with 28 programs across 10 companies. The most active players are Sanofi, Band Therapeutics, Octapharma. 15 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

22/100

Mech. Concentration

50/100

Completion Rate

78/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1B

Band Therapeutics

1 program

Phase 2Octapharma logo

Octapharma

2 programs

Phase 3V

Vega Therapeutics, Inc

1 program

Phase 3A

Amring

1 program

Phase 3Takeda logo

Takeda

5 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

20 of 24 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme313%Monoclonal antibody14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

34

clinical trials

Completed18 · 53%
Recruiting9 · 26%
Terminated4 · 12%
Available1 · 3%
Not yet recruiting1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

34 trials

Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease
Recruiting·MMedical University of Vienna·Phase 2·NCT07273721·6 enrolled
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Recruiting·VVega Therapeutics, Inc·Phase 3·NCT07115004·60 enrolled
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Recruiting·Takeda logoTakeda·Phase 3·NCT05582993·24 enrolled
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Recruiting·BBleeding and Clotting Disorders Institute Peoria, Illinois·Phase 1·NCT05500807·40 enrolled
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
Recruiting·Takeda logoTakeda·N/A·NCT07404644·13 enrolled
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
Recruiting·Takeda logoTakeda·Phase 3·NCT07129343·20 enrolled
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Recruiting·Grifols Therapeutics LLC logoGrifols Therapeutics LLC·Phase 4·NCT02472665·8 enrolled
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Recruiting·VVega Therapeutics, Inc·Phase 1/2·NCT05776069·116 enrolled
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Recruiting·BBaxalta now part of Shire·Phase 3·NCT02932618·31 enrolled
Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Not yet recruiting·—·N/A·NCT07410130·25 enrolled
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Completed·CSL Behring logoCSL Behring·N/A·NCT04657887·135 enrolled
The Von Willebrand Disease (VWD) International Prophylaxis Study
Completed·SSkane University Hospital·N/A·NCT00557908·105 enrolled
A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.
Completed·BBio Products Laboratory·Phase 2·NCT02250508
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
Completed·BBaxalta now part of Shire·Phase 3·NCT02283268·24 enrolled
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Completed·BBaxalta now part of Shire·Phase 3·NCT03879135·38 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)